Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Ben Chu: GlaxoSmithKline is somewhere between a giant tiger and a fly for China's leadership

The abject apology issued by Glaxo’s chief executive underlines the company's subordinate status

Ben Chu
Friday 19 September 2014 22:32 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Xi Jinping, China’s paramount leader, has pledged to both swat “flies” and catch “tigers” in his crusade against endemic corruption. That has been interpreted as meaning he intends to crack down equally on petty chiselling bureaucrats and also the mighty robber barons. So where do GlaxoSmithKline and its head of operations in China, Mark Reilly, fit in?

At first glance Glaxo, a deep-pocketed, foreign multinational, seems like a Tiger. And yet in another respect Glaxo and Reilly are more insect-like. For one thing the crimes of which Glaxo has been found guilty – bribing doctors to promote its products – are nothing extraordinary by Chinese standards. The medical industry, where doctors are low-paid, is notorious for this kind of thing.

For another, multinationals are not centres of political power in China as they are in parts of the West. They are supplicants, desperate to be allowed access to the vast domestic market by the protectionist Beijing authorities.

The abject apology issued by Glaxo’s chief executive, Sir Andrew Witty, underlined this subordinate status. This whole business remains opaque. We do not know enough to say for certain what lay behind the prosecution. But what we can say is that it brings home the profound risks facing foreign firms – whether Tigers or flies – that operate in China.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in